DALLAS, April 14, 2014 /PRNewswire/ --
ReportsnReports.com offers Geriatric Medicine Development - Carving out New Opportunities to Treat Age-related Diseases 2014 market research report in its store at http://www.reportsnreports.com/reports/280698-geriatric-medicine-development-carving-out-new-opportunities-to-treat-age-related-diseases.html .
Geriatric Medicine Development - Carving out New Opportunities to Treat Age-related Diseases report says despite the elderly being the fastest-growing segment of the global population, only a few of their treatments have been clinically trialed in age-appropriate patients, with many of their therapies still not available in suitable formulations and dosages. The research says many older people suffer from comorbid conditions and one in three takes at least five drugs or more on a daily basis. This significantly increases the risk of Adverse Drug Events and hospitalization, with up to one third of elderly emergency admissions being drug-related. Request a sample of this report at http://www.reportsnreports.com/contacts/RequestSample.aspx?name=280698 .
The report states that off-label prescriptions are common for older patients, as pre-marketing drug trials often exclude geriatric patients and approved doses are not likely to be appropriate for the elderly. Antipsychotic medications, for example, are regularly prescribed off-label in up to 80% of care-home patients, to manage delirium, agitation and psychosis resulting from Alzheimer's disease and schizophrenia. However, these drugs have been associated with an increased risk of diabetes, cerebrovascular events and death, according to the report.
In 2010, the International Conference on Harmonisation (ICH) updated its E7 guidelines, which determined that the number of older patients should be representative of the study population and not limited to 100 patients, as previously indicated. Additionally, ICH E7 recommended that people aged 75 years and older should be incorporated in clinical trials, including those with comorbidities using concomitant therapies.
Geriatric Medicine Development - Carving out New Opportunities to Treat Age-related Diseases research believes that the development of age-appropriate formulations and doses could allow for smarter prescriptions of approved drugs, such as anti-coagulants, anti-diabetic agents, antipsychotics and analgesics in older people. Additionally, new opportunities exist for companies to develop medicines for age-related diseases, including cognitive impairment, sarcopenia and neurodegenerative diseases.
Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=280698 .
Table of Contents for Geriatric Medicine Development - Carving out New Opportunities to Treat Age-related Diseases 2014 research report covers:
Geriatric medicines: an overview
Unmet clinical needs
Political will for change
Strategic considerations for developing geriatric medicines
Barriers to developing geriatric drugs
Clinical trial considerations
"Big data's" role in identifying treatment gaps and commercial opportunities
Raising physician and patient awareness
Commercial opportunities to address the treatment gap
Improving existing therapies
New therapeutic opportunities
Vaccine Development Strategies - Refocusing Efforts to Address New Challenges 2014 research report provides readers with an understanding of the key developing trends in the vaccines market and how these are expected to impact on the overall competitive landscape, the major players and forecasted growth. This report provides an overview of the preventative vaccines market, including insights into clinical development strategies, recommendations for maximizing potential for development of preventative vaccines and discussion about potential areas of growth in the near term. The report provides in-depth analysis of the developing landscape for therapeutic vaccines, including recent activities of major pharmaceutical companies, insight into the challenges being faced by companies developing therapeutic vaccines and recommendations on clinical development strategies to overcome these potential obstacles and hurdles. The report assesses the evolving competitive vaccines landscape, profiling the major pharmaceutical players and providing information into the emerging vaccines companies and assessing how the vaccines market is expected to develop in the short to medium term. Complete report is available at http://www.reportsnreports.com/reports/280699-vaccine-development-strategies-refocusing-efforts-to-address-new-challenges.html .
2014 Global Blood Banking Market Overview - Facilities, Test Volumes, and Sales Forecasts for Typing, Grouping and Infectious Disease Screening Tests by Country is a report that provides a worldwide overview of the blood banking market, including estimates of facilities performing blood banking tests, as well as test volume, reagent and instrument sales forecasts for blood typing, grouping and infectious disease screening tests by country. Read more at http://www.reportsnreports.com/reports/280660-2014-global-blood-banking-market-overview-facilities-test-volumes-and-sales-forecasts-for-typing-grouping-and-infectious-disease-screening-tests-by-country.html .
Global Glaucoma Therapeutics Market 2014-2018 research report says the industry is set to grow at 2.53% CAGR to 2018. Key companies discussed in this report include Allergan Inc, Merck & Co. Inc, Novartis AG and Pfizer Inc. Other vendors mentioned in this research are Acadia Pharmaceuticals Inc., AC Immune SA, Acorn Biomedical Inc., Advanced Cell Technology Inc., Aerie Pharmaceuticals Inc., Carl Zeiss Meditec Inc., Falcon Pharmaceuticals Ltd., Inotek Pharmaceuticals Corp., Lexicon Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., NicOx SA, Otsuka Holdings Co. Ltd., Phytopharm plc, Santen Pharmaceuticals Co. Ltd., Senju Pharmaceutical Co. Ltd., SIFI SpA and Valeant Pharmaceuticals International Inc. Complete report is available at http://www.reportsnreports.com/reports/280690-global-glaucoma-therapeutics-market-2014-2018.html .
2014 Deep Research Report on Global and China Insulin Industry profiles companies like Novo Nordisk, Sanofi, Eli Lilly, Bioton, Dongbao, Gan & Lee and United Laboratories (TUL). This report provides a new project SWOT analysis as well as investment feasibility analysis information along with 140+ supporting data tables and figures. Complete report is available at http://www.reportsnreports.com/reports/280629-2014-deep-research-report-on-global-and-china-insulin-industry.html .
Explore more reports by CBR Pharma Insights at http://www.reportsnreports.com/publisher/cbr-pharma-insights/ .
ReportsnReports.com is an online market research reports library of 400,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Connect With Us on: